In the first half of this year，National & ldquo; Limit & rdquo;、& ldquo; Price reduction & rdquo; Policy has a greater impact on the company of chemical raw drugs。
Taking the domestic VC production leading company Northeast Pharmaceutical as an example，Lost 120 million yuan in the first half of 2012，decreased by 3070.24%year -on -year。Under the above situation，R & D power、The reserves of the new drug and new project will have a significant impact on future competitive patterns。As of now，12 Chemicals and Pharmaceutical My stake betting appListed stake sports betting appCompanies，There are 70 research projects in total。Among them, the most project is Northeast Pharmaceutical，A total of 18 items，Followed by Jincheng Medicine, which was listed in July 2011，A total of 13 items。
Vitamin: Research on the Research of Pharmaceutical Reinforcement Preparation
At present, the export of vitamin production enterprises is restricted in stock，In the first half of the year, vitamin C excesss 200,000 tons，Industry leading Northeast Pharmaceuticals is also in trouble。Analyst analyst in the pharmaceutical industry in a securities firm in the north told the wealth reporter，Before 2011，The company's research and development capabilities are general，Products are mostly traditional products and imitation drugs，Full Chemical Synthetic Nopardia has independent intellectual property rights，In recent years, it has not made much investment in R & D，Small new products，Mainly re -developed old products。
but 2011，Northeast Pharmaceutical in product planning、Patent、Progressive progress in the aspects of stake betting appMy stake betting appindustry -university -research cooperation。formed & ldquo; Twelfth Five -Year Plan; Product Development Planning and 3 sub -planning; signing with Shenyang University of Chemical Technology and Shenyang Pharmaceutical University，Construction & ldquo; Academician expert workstation & rdquo;，Building a technical innovation industry -university -research strategy alliance。In 2011, 8 new application for invention patents，Development in more than 20 directional products。
Antibiotics: Jincheng Pleubao glutath glutathione
Jincheng Pharmaceutical, which has changed as soon as the listing performance, is mainly the Baobao glutathione project。
Researcher Peng Haizhu, a researcher at Huatai Securities, thinks，The glutathione project will promote the company's performance reversal，It is expected that glutathione will become the company's main source of performance。
The company's glutathione project will be constructed in the second half of the year，It is expected to reach the birth around September next year。
At present, the demand for the annual demand for the raw materials of glutathione is nearly 100 tons and basically dependent on imports，After the company's product gets the raw materials, it will enter the domestic glutathione drug market。The company is also actively developing overseas markets，Products are reporting to the European Union DMF。The production threshold for production of glutathione raw materials is high and the downstream demand growth rate is faster，Still in the seller's market status，At present, the world's major manufacturers are only Japanese coordinating fermentation and Yili I.C.I。
The rest and 12 items，There are 6 in the small test project and research stage。In addition, the company's cardiovascular stake online sports bettingand stake online sports bettingcerebrovascular and anti -tumor products have made progress smoothly，Drug registration related procedures are stepping up。
Hormonal: Tianga impacts the international high -end market
Tiang Pharmaceutical Co., Ltd. is currently the largest production base for corticosteroids in my country，The main products include Landmisone、Dolly Mi Song、Bomonatsu, etc.，Also produce a small amount of cardiovascular and raw materials。Micatein and propionic acid fluchibatticatson two new products obtained the new version of GMP certificate in March 2012，Among them, mamsonic acid mamong has begun to form commercial procurement，Vorlcataton is developing the market。
The newly developed metamolon nylon tablets have submitted the application documents of generic drugs to the US FDA and obtained confirmation，Enter the review stage。
SLXB capsule product developed cooperated with the Institute of Research Institute has completed the early technology development work，The clinical trial of biological equivalent in the second half of 2012。In the first half of 2012, there were 11 technical research projects and 4 quality research projects.。
For the new standard of the European Pharmacopoeia 7.5, which will take effect in July 2012，The company's 2 varieties are actively carrying out the research plan and obtaining a certain breakthrough，It is expected to open the door of the international high -end market。
